Clinical Trial Update: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. [Phase 3]

View source ↗

Summary

Phase III clinical trial of NPB-01 for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis unresponsive to corticosteroids has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stevens-johnson Syndrome
• Toxic Epidermal Necrolysis

Drugs mentioned

• NPB-01

Snippet

Sponsor: Nihon Pharmaceutical Co., Ltd | Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Phase 3 | Status: COMPLETED